Clinical Trial Update: Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating concurrent chemoradiation with pembrolizumab, followed by pembrolizumab and olaparib, in newly diagnosed treatment-naïve limited-stage …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Lynparza (olaparib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING